TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fat detection thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death or major stroke
Endpoint domain: Mortality/survival
Primary endpoint: neurological death or major ipsilateral stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in 2 hour glucose in OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Body Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor antigen specific T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average of acute serious bacterial infections
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammation status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Muscle strength evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of VRR on ICU
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic Sensitivity (AHI≥5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Sensitivity (AHI≥15)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Sensitivity (AHI≥30)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Specificity (AHI≥5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Specificity (AHI≥15)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Specificity (AHI≥30)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of CKD-348(6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CKD-348(6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The incidence of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of moderate and severe diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Burden of disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with serious and non-serious treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant laboratory abnormalities or changes in laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with TEAEs leading to the discontinuation of ferric citrate
Endpoint domain: Adverse events/effects
Primary endpoint: Acquisition of transthoracic echocardiography media
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with New Malignancies and Recurrence of Pre-existing Malignancy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with New Incidence or Exacerbation of a Pre-existing Neurologic Disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with New Incidence of Grade >= 3 Infection
Endpoint domain: Adverse events/effects
Primary endpoint: muscle inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of Xpert MTB/RIF Ultra
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Specificity of Xpert MTB/RIF Ultra
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to perform block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: FRAQOL composite score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Antimicrobial Resistance (AMR) of Conjunctiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Antimicrobial Resistance (AMR) of Nasopharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Antimicrobial Resistance (AMR) of Oral
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Antimicrobial Resistance (AMR) of Gut
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Completion rate of baseline and follow up data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of medication changes recommended and implemented
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sustainability of intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity and specificity in triage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline on the Hospital Anxiety and Depression Scale (HADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline on NIH Toolbox Perceived Stress Survey (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline on Single-item Sleep Quality Scale (SQS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Time to glottis visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tear lipid layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average ARC Total Combined Score (TCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT) for LANRA
Endpoint domain: Adverse events/effects
Primary endpoint: Maximally Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of LANRA in Combination With Standard Doses of Gilteritinib
Endpoint domain: Adverse events/effects
Primary endpoint: Postobturation pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of Superoxide Dismutase (SOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pancreatic and duodenal homeobox 1 (PDX-1) expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Freedom from Recurrence at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Negative experience score CPSS-5-S
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inattention, impulsivity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Group B Streptococcus (GBS) screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area under the glucose curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in FVC%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of ER visits, hospitalizations for cardiovascular causes
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Objective tumor response rate1 (ORR1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective tumor response rate 2 (ORR2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Engagement through Action Plan Initiation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Long-term safety of Pompe disease treatments
Endpoint domain: Adverse events/effects
Primary endpoint: Complete or partial renal remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of respiratory illnesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Change in Daily Physics Emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Daily Responses to Physics Emotions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Daily Threat vs. Challenge Appraisals
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Daily Physics Engagement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Major Pathologic Response (MPR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Who Schedule Professional Treatment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Symptom Response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Patients Receiving Any Home Dialysis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: EORTC QLQ C-30- CIPN20 Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain Assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Serum creatinine removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Achieving Clinical Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrency of TR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power Density Spectrum Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ERP MMN Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Current PrEP status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PrEP uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of doses taken at 6 weeks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of doses taken at 3 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Affective states - relaxation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Affective states - contentment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Affective states - happiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Affective states - stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Affective states - motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Affective states - tension
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: blood-oxygen-level-dependent (BOLD) signal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Referral status by healthcare professional
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: dp/dt fluids dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of New-onset Chronic Medical Conditions (NOCMCs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Serious Adverse Event (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Vimentin Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers in colon mucosa, precancerous lesions and colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blood Glucose Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Satiety Response Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical utility of Compcyst in pancreatic cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: steroid-sparing effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genotype of early-onset developmental epileptic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of umbilical hernia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Level of interleukin-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total number of medications that have been deprescribed since enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Resident's quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in calorie intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Coronary arterial calcium score (CACS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severe maternal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annualized rate of major asthma exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Sessions completed
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Intra-cortical inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Complete remission rate of oral ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: optimal MAP during NIRS-based measurement of cerebrovascular autoregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: delirium and postoperative NCD after surgery (composite)
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of patients with peripheral sensory neuropathy grade ≥ 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: variation of 12-item neurotoxicity questionnaire (Ntx- 12) total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: variation in grades of mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Information understanding and retention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: House-Brackmann grading system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: electroneuronography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma glucose iAUC (T0 - T120min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child Post-Traumatic Stress Reaction Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline on the log scale in high-sensitivity C-reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first occurrence of CV death or MI
Endpoint domain: Mortality/survival
Primary endpoint: Level of Parental Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Level of Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total number of suicidal behaviours
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of first episode of N. gonorrhoeae
Endpoint domain: Adverse events/effects
Primary endpoint: Overall incidence of all episodes of N. gonorrhoeae infection
Endpoint domain: Adverse events/effects
Primary endpoint: Recruitment and adherence to protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility - Time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility - Cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in social support (Emotional Support)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in children's behavior (DECA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak concentrations (Cmax) of total and free plasma ropivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravascular clotting during CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intravascular clotting after termination of CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time from cardiac arrest to first clot during CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time from cardiac arrest to first clot after termination of CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quality of life assessed by EORTC QLQ-H&N35
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The most intense pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectral power analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha rhythm frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Source localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of subjects with score of 2 or 3 on Clinician Global Aesthetic Improvement (CGAIS) scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of subjects with score of 2 or 3 on Subject Global Aesthetic Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area Under Serum Concentration Versus Time Curve (AUCtau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Serum Concentration Immediately Prior to the Next Study Treatment Administration (Ctrough)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with AE by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: clinical frailty levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hydration status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photogrammetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myotonometric assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20 response criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28-CRP activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of treatment with ELGN-2112
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rate of diabetic retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Detection rate of macular oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Eradication of rCDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Agreement of individual sperm cell's classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of the Q300 device results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intracranial local recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of drug allergic reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Survival at CRRT Discontinuation
Endpoint domain: Mortality/survival
Primary endpoint: Survival at intensive care unit (ICU) discharge
Endpoint domain: Mortality/survival
Primary endpoint: Change in estimated ASCVD risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fidelity summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum Plasma concentration observed (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from the time of dosing to the last measurable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve extrapolated to infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG waveforms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Goal Attainment Scale (GAS T) score at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average Goal Attainment Scale (GAS T) score at 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients who achieve GAS-T score ≥0 for impairment/ symptoms goal
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Local recurrence of cervical cancer
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of transient loss of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of different diagnoses leading to transient loss of consciousness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in sleep timing
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Cricoid force necessary to occlude esophageal entrance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PERG amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PERG latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inspiratory O2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes